Literature DB >> 3129686

The reciprocal partners of both the t(14; 18) and the t(11; 14) translocations involved in B-cell neoplasms are rearranged by the same mechanism.

Y Tsujimoto1, E Louie, M M Bashir, C M Croce.   

Abstract

Both the t(14; 18) and the t(11; 14) chromosomal translocations are associated with human B-cell neoplasms. Sequence analysis of the regions on chromosomes 18q- and 11q- involved in the joining of chromosomes 14 and 18 and of chromosomes 11 and 14 during their respective translocations indicates the involvement of the DH region. There is a deletion of the region between the involved D segment and the JH region, and extranucleotides are present at the joining sites on the 18q- and on the 11q- chromosomes. We have previously reported that the joining region on chromosome 14q+ involved in both the t(11; 14) and the t(14; 18) translocations are structurally identical. We now report that the joining regions on chromosomes 11q- and 18q- involved in these two different translocations are also identical. Thus, these translocations arose by the same mechanisms. The deletions of the region between the involved segment and the JH region must likely occur during either a D-J recombination event on the 18q- and 11q- chromosomes following the translocations or, alternatively, during the D-J recombination event that results in the translocation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3129686

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  12 in total

1.  The down-regulation of miR-125b in chronic lymphocytic leukemias leads to metabolic adaptation of cells to a transformed state.

Authors:  Esmerina Tili; Jean-Jacques Michaille; Zhenghua Luo; Stefano Volinia; Laura Z Rassenti; Thomas J Kipps; Carlo M Croce
Journal:  Blood       Date:  2012-06-21       Impact factor: 22.113

Review 2.  The molecular biology of B-cell lymphoma: clinicopathologic implications.

Authors:  P M Kluin; J H van Krieken
Journal:  Ann Hematol       Date:  1991-04       Impact factor: 3.673

Review 3.  Ontogeny, Genetics, Molecular Biology, and Classification of B- and T-Cell Non-Hodgkin Lymphoma.

Authors:  Russell James Hubbard Ryan; Ryan Alan Wilcox
Journal:  Hematol Oncol Clin North Am       Date:  2019-05-18       Impact factor: 3.722

Review 4.  Malleable immunoglobulin genes and hematopathology - the good, the bad, and the ugly: a paper from the 2007 William Beaumont hospital symposium on molecular pathology.

Authors:  Adam Bagg
Journal:  J Mol Diagn       Date:  2008-08-07       Impact factor: 5.568

5.  Evolution of B-cell malignancy: pre-B-cell leukemia resulting from MYC activation in a B-cell neoplasm with a rearranged BCL2 gene.

Authors:  C E Gauwerky; F G Haluska; Y Tsujimoto; P C Nowell; C M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

Review 6.  Apoptosis in the development of the immune system: growth factors, clonal selection and bcl-2.

Authors:  N J McCarthy; C A Smith; G T Williams
Journal:  Cancer Metastasis Rev       Date:  1992-09       Impact factor: 9.264

7.  Involvement of the TCL5 gene on human chromosome 1 in T-cell leukemia and melanoma.

Authors:  L R Finger; J Kagan; G Christopher; J Kurtzberg; M S Hershfield; P C Nowell; C M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

8.  V(D)J-mediated translocations in lymphoid neoplasms: a functional assessment of genomic instability by cryptic sites.

Authors:  Rodrig Marculescu; Trang Le; Paul Simon; Ulrich Jaeger; Bertrand Nadel
Journal:  J Exp Med       Date:  2002-01-07       Impact factor: 14.307

9.  BCL2 oncogene translocation is mediated by a chi-like consensus.

Authors:  R T Wyatt; R A Rudders; A Zelenetz; R A Delellis; T G Krontiris
Journal:  J Exp Med       Date:  1992-06-01       Impact factor: 14.307

10.  Clonal expansion in follicular lymphoma occurs subsequent to antigenic selection.

Authors:  A D Zelenetz; T T Chen; R Levy
Journal:  J Exp Med       Date:  1992-10-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.